Vyse S - Search Results

1

Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer.

Vyse S, Huang PH. Vyse S, et al. Expert Rev Anticancer Ther. 2022 Jan;22(1):3-16. doi: 10.1080/14737140.2022.2016397. Epub 2021 Dec 28. Expert Rev Anticancer Ther. 2022. PMID: 34913823 Free PMC article.

2

Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.

Vyse S, Howitt A, Huang PH. Vyse S, et al. J Mol Biol. 2017 Jun 16;429(12):1767-1786. doi: 10.1016/j.jmb.2017.04.018. Epub 2017 May 3. J Mol Biol. 2017. PMID: 28478283 Free PMC article. Review.

3

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer.

Vyse S, Huang PH. Vyse S, et al. Signal Transduct Target Ther. 2019 Mar 8;4:5. doi: 10.1038/s41392-019-0038-9. eCollection 2019. Signal Transduct Target Ther. 2019. PMID: 30854234 Free PMC article. Review.

4

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.

Harrison PT, Vyse S, Huang PH. Harrison PT, et al. Among authors: vyse s. Semin Cancer Biol. 2020 Apr;61:167-179. doi: 10.1016/j.semcancer.2019.09.015. Epub 2019 Sep 25. Semin Cancer Biol. 2020. PMID: 31562956 Free PMC article. Review.

5

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.

Pacini L, Jenks AD, Vyse S, Wilding CP, Arthur A, Huang PH. Pacini L, et al. Among authors: vyse s. Pharmgenomics Pers Med. 2021 Mar 9;14:301-317. doi: 10.2147/PGPM.S242045. eCollection 2021. Pharmgenomics Pers Med. 2021. PMID: 33727854 Free PMC article. Review.

6

Exploiting receptor tyrosine kinase co-activation for cancer therapy.

Tan AC, Vyse S, Huang PH. Tan AC, et al. Among authors: vyse s. Drug Discov Today. 2017 Jan;22(1):72-84. doi: 10.1016/j.drudis.2016.07.010. Epub 2016 Jul 21. Drug Discov Today. 2017. PMID: 27452454 Free PMC article. Review.

7

Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.

Maguire SL, Peck B, Wai PT, Campbell J, Barker H, Gulati A, Daley F, Vyse S, Huang P, Lord CJ, Farnie G, Brennan K, Natrajan R. Maguire SL, et al. Among authors: vyse s. J Pathol. 2016 Nov;240(3):315-328. doi: 10.1002/path.4778. J Pathol. 2016. PMID: 27512948 Free PMC article.

8

Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer.

Todd JR, Ryall KA, Vyse S, Wong JP, Natrajan RC, Yuan Y, Tan AC, Huang PH. Todd JR, et al. Among authors: vyse s. Oncotarget. 2016 Sep 27;7(39):62939-62953. doi: 10.18632/oncotarget.11307. Oncotarget. 2016. PMID: 27556857 Free PMC article.

9

Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.

Vyse S, McCarthy F, Broncel M, Paul A, Wong JP, Bhamra A, Huang PH. Vyse S, et al. J Proteomics. 2018 Jan 6;170:130-140. doi: 10.1016/j.jprot.2017.08.015. Epub 2017 Aug 24. J Proteomics. 2018. PMID: 28842319 Free PMC article.

10

Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer.

Jenks AD, Vyse S, Wong JP, Kostaras E, Keller D, Burgoyne T, Shoemark A, Tsalikis A, de la Roche M, Michaelis M, Cinatl J Jr, Huang PH, Tanos BE. Jenks AD, et al. Among authors: vyse s. Cell Rep. 2018 Jun 5;23(10):3042-3055. doi: 10.1016/j.celrep.2018.05.016. Cell Rep. 2018. PMID: 29874589 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters